A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008) - Trial NCT06295796
Access comprehensive clinical trial information for NCT06295796 through Pure Global AI's free database. This Phase 1 trial is sponsored by Merck Sharp & Dohme LLC and is currently Not yet recruiting. The study focuses on Renal Impairment. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Merck Sharp & Dohme LLC
Timeline & Enrollment
Phase 1
Jun 24, 2024
Apr 21, 2025
Primary Outcome
Area under the concentration versus time curve from time 0 to last quantifiable sample (AUC0-last) of MK-8527 in plasma,Area under the concentration versus time curve from time 0 to infinity (AUC0-inf) of MK-8527 in plasma,Maximum concentration (Cmax) of MK-8527 in plasma,Time to Maximum concentration (Tmax) of MK-8527 in plasma,Apparent terminal half-life (t1/2) of MK-8527 in plasma,Apparent Clearance (CL/F) of MK-8527 in plasma,Apparent volume of distribution during terminal phase (Vz/F) of MK-8527 in plasma
Summary
The goal of this study is to evaluate the effect of moderate and severe renal impairment (RI)
 on the pharmacokinetics (PK), safety, and tolerability of MK-8527. There will be no
 hypothesis testing in the study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06295796
Non-Device Trial